Get the Stockscreener App
3.785
7.18%
-0.395
Genelux Corp stock is traded at $3.785, with a volume of 154.30K.
It is down -7.18% in the last 24 hours and up +9.92% over the past month.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
See More
Previous Close:
$4.18
Open:
$4.2
24h Volume:
154.30K
Relative Volume:
0.75
Market Cap:
$141.26M
Revenue:
-
Net Income/Loss:
$-28.30M
P/E Ratio:
-3.1281
EPS:
-1.21
Net Cash Flow:
$-21.30M
1W Performance:
-17.45%
1M Performance:
+9.92%
6M Performance:
+86.54%
1Y Performance:
-46.63%
1-Day Range:
$3.80
$4.2412
1-Week Range:
$3.83
$4.7437
52-Week Range:
$1.60
$7.32
Genelux Corp Stock (GNLX) Company Profile
Name
Genelux Corp
Sector
Industry
Phone
805-267-9889
Address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
3.80 | 141.26M | 0 | -28.30M | -21.30M | -1.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.63 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.61 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
635.59 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.60 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.72 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-24 | Initiated | Guggenheim | Buy |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Nov-27-23 | Initiated | H.C. Wainwright | Buy |
| Sep-12-23 | Initiated | Maxim Group | Buy |
| Feb-15-23 | Initiated | The Benchmark Company | Speculative Buy |
Genelux Corp Stock (GNLX) Latest News
Why Genelux Corporation (GNLX) is Skyrocketing So Far in 2025 - Yahoo Finance
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
D.A. Davidson & CO. Makes New $51,000 Investment in Genelux Co. (NASDAQ:GNLX) - Defense World
Apollon Wealth Management LLC Grows Stock Holdings in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux Corporation (NASDAQ:GNLX) Announces CFO Transition and Appointment of New CFOGenelux Corporation, a leading biotechnology company, recently disclosed in an SEC filing that Lourie Zak has resigned as Chief Financial Officer, effective imm - Defense World
Genelux Corporation Announces Matt Pulisic Serves as Principal Financial Officer and Principal Accounting Officer - Marketscreener.com
Genelux appoints new CFO as Lourie Zak departs - MSN
Genelux Corporation Announces New Chief Financial Officer - Markets Insider
Genelux appoints new CFO amid clinical advancements - Investing.com
Genelux Corp. Appoints New CFO Amid Leadership Change - TipRanks
Genelux Names Matthew Pulisic as CFO -February 03, 2025 at 10:40 am EST - Marketscreener.com
Oncolytic Viruses Market Expected to rise, 2034 | Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen - Barchart
Genelux (GNLX) Stock Price, News & Analysis - MarketBeat
We Think Genelux (NASDAQ:GNLX) Needs To Drive Business Growth Carefully - Yahoo Finance
Could Genelux's Olvi-Vec Emerge As A Powerful Tool In The Fight Against Difficult-to-treat Cancers? - RTTNews
Geode Capital Management LLC Has $749,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux director Tyree James L sells shares worth $8,511 - Investing.com India
Genelux director Tyree James L sells shares worth $8,511 By Investing.com - Investing.com Nigeria
XTX Topco Ltd Invests $59,000 in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux VP sells shares worth $14,742 By Investing.com - Investing.com Australia
Genelux CFO Zak Lourie sells $4,921 in stock By Investing.com - Investing.com Australia
Genelux's head of regulatory sells $5,873 in stock By Investing.com - Investing.com Australia
Genelux CFO Zak Lourie sells $4,921 in stock - Investing.com
Genelux CEO Zindrick Thomas sells $33,497 in stock - Investing.com
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright - Yahoo Finance
HC Wainwright Cuts Genelux (NASDAQ:GNLX) Price Target to $30.00 - Defense World
Genelux shares target cut, maintains buy rating on 3Q earnings - Investing.com
Genelux reports Q3 EPS (19c), consensus (19c) - TipRanks
These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts - TipRanks
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates - GlobeNewswire
Genelux Corp. Releases New Corporate Presentation - TipRanks
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference - Yahoo Finance
Genelux CEO to Present at Guggenheim Healthcare Innovation Conference - StockTitan
Individual investors who hold 56% of Genelux Corporation (NASDAQ:GNLX) gained 34%, institutions profited as well - Yahoo Finance
Guggenheim Begins Coverage on Genelux (NASDAQ:GNLX) - Defense World
Guggenheim sees upside in Genelux shares, targets $8 as pivotal cancer trial progresses - Investing.com India
Brokerages Set Genelux Co. (NASDAQ:GNLX) PT at $22.33 - MarketBeat
Highbridge Capital Management LLC Acquires Significant Stake in Genelux Corp - Yahoo Finance
Genelux doses first subject in Phase II trial of NSCLC treatment - Yahoo Finance
Genelux advances NSCLC treatment with Phase 2 Olvi-Vec trial - Investing.com
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer - Yahoo Finance
Cubist Systematic Strategies LLC Takes $56,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux Co. (NASDAQ:GNLX) Shares Sold by Renaissance Technologies LLC - Defense World
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit - Yahoo Finance
Genelux announces executive departure By Investing.com - Investing.com Australia
Genelux announces executive departure - Investing.com
Point72 Asia Singapore Pte. Ltd. Acquires Shares of 20,162 Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux Corp Stock (GNLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.91%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):